Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children | Zendy

Thanyawee Puthanakit | Zendy; Jasper van der Lugt | Zendy; Torsak Bunupuradah | Zendy; Jintanat Ananworanich | Zendy; Meena Gorowara | Zendy; Chayapa Phasomsap | Zendy; Thidarat Jupimai | Zendy; Pitch Boonrak | Zendy; Chitsanu Pancharoen | Zendy; David M. Burger | Zendy; Kiat Ruxrungtham | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children

Author(s) -

Thanyawee Puthanakit,

Jasper van der Lugt,

Torsak Bunupuradah,

Jintanat Ananworanich,

Meena Gorowara,

Chayapa Phasomsap,

Thidarat Jupimai,

Pitch Boonrak,

Chitsanu Pancharoen,

David M. Burger,

Kiat Ruxrungtham

Publication year - 2009

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkp322

Subject(s) - lopinavir , ritonavir , lopinavir/ritonavir , pharmacokinetics , protease inhibitor (pharmacology) , medicine , pharmacology , human immunodeficiency virus (hiv) , virology , antiretroviral therapy , viral load

Lopinavir/ritonavir is a common protease inhibitor (PI) used for second-line regimens in children. Several studies have shown higher plasma concentrations of antiretroviral agents in Thai adults than in Caucasians, suggesting that lower doses may be used.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research